Actuate Therapeutics Inc
NASDAQ:ACTUBiotechnology
+$0.06 today
- Market cap
- $50.01M
- Beta
- 0.53
- P/E (TTM)
- -2.3
- EPS (TTM)
- -$0.92
Volume 0.03M
Average 0.16M
ACTU Interest Expense
Cost of servicing the company's debt during the period.
Actuate Therapeutics IncNASDAQ: ACTU
Interest Expense · Q1 FY2026 · quarter ended Mar 2026
Interest expense dips below year-ago levels
Q1 FY2026 interest expense of $5.06K fell 0.0% year over year, behind the +8.3% change in trailing-twelve-month interest expense. Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at +7.7% a year.
Context
- Interest expense increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -0.0% toward the trailing-twelve-month pace of +8.3%.
Sources:Income StatementText generated from reported figures; not investment advice.
Interest Expense history
USD · from the income statement
- Latest · FY2025
- 20.25K USD
- Year-over-year change
- +208.2%
- 3-year CAGR
- +7.7%
| Period | Period end | Interest Expense | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 20.25K | +208.2% |
| FY2024 | 2024-12-31 | (18.72K) | -142.9% |
| FY2023 | 2023-12-31 | 43.64K | +169.4% |
| FY2022 | 2022-12-31 | 16.2K | — |
Interest Expense vs competitors
How ACTU compares with its peers on the latest reported figures
- Peers report in different currencies, so interest expense is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +8.3% is the 3rd highest of 4, against a peer median of +45.1%.
- Over three fiscal years its annual growth of +7.7% compares with a peer median of -50.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
ELTXElicio Therapeutics, Inc. | LTM Mar 2026 | $1.36M USD | +128.9% | -32.0% | — |
| LTM Mar 2026 | CHF 45.01K CHF | +45.1% | -69.7% | — | |
ACTUActuate Therapeutics Inc | LTM Mar 2026 | $20.25K USD | +8.3% | +7.7% | — |
| LTM Mar 2026 | $0 USD | — | — | — | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| LTM Mar 2026 | $0 USD | — | — | — | |
| LTM Mar 2026 | $0 USD | — | — | — | |
| LTM Mar 2026 | $0 USD | -100.0% | — | 0.0% | |
| Peer median (excluding ACTU) | — | +45.1% | -50.8% | 0.0% | |
Competitors are the stored peer set for ACTU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — |
| Research & Development | 16.39M | 21.71M | 18.68M | 10.29M |
| Selling, General & Admin | 3.82M | 3.27M | 6.48M | 12.2M |
| Operating Expenses | 20.21M | 24.97M | 25.16M | 22.5M |
| Depreciation & Amortization | 63.61K | 272.85K | 2.14M | 0 |
| EBITDA | (20.08M) | (24.43M) | (25.16M) | (22.21M) |
| EBITDA Margin | — | — | — | — |
| Operating Income | (20.21M) | (24.97M) | (25.16M) | (22.5M) |
| Operating Margin | — | — | — | — |
| Interest Income | 27.03K | 352.67K | 222.29K | 287.71K |
| Interest Expense | 16.2K | 43.64K | (18.72K) | 20.25K |
| Other Income / Expenses | 47.41K | 229.21K | (2.12M) | 267.46K |
| Income Before Tax | (20.16M) | (24.74M) | (27.28M) | (22.23M) |
| Pre-Tax Margin | — | — | — | — |
| Income Tax Expense | 0 | 0 | 800 | 0 |
| Net Income | (20.16M) | (24.74M) | (27.29M) | (22.23M) |
| Net Margin | — | — | — | — |
| EPS (Basic) | (1.34) | (1.65) | (3.26) | (1.06) |
| EPS (Diluted) | (1.34) | (1.65) | (3.26) | (1.06) |
| Weighted Avg Shares | 15.03M | 15.03M | 19.51M | 21.02M |
| Weighted Avg Shares (Diluted) | 15.03M | 15.03M | 19.51M | 21.02M |
Actuate Therapeutics Inc
NASDAQ:ACTU
Intrinsic Alpha fair value
Locked
Current Price
$2.09
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.